The TADPOLE Challenge has identified better ways to predict the development of Alzheimer’s disease (AD) that may improve the selection of patients for clinical trials, researchers have reported.
One possible reason why many trials in AD conducted to date have failed is that they may have included the wrong patients, according to Dr Razvan Marinescu of University College London, UK. Better methods for predicting the AD development could therefore improve clinical trial design.
As part of The Alzheimer’s Disease Prediction of Longitudinal Evolution (TADPOLE) challenge, Dr Marinescu and colleagues assessed 92 algorithms submitted by 33 international teams.
Vuoi saperne di più?
Accedi o registrati per accedere a tutti i contenuti di Neurodiem.
Hai già un account? Accedi
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.